logo-loader
viewImmuPharma PLC

Immupharma chairman 'delighted' with first significant investment from specialist US funds

ImmuPharma PLC's (LON:IMM) Tim McCarthy speaks to Proactive London's Andrew Scott following the news of new funding through two specialist US healthcare investors. Up to US$6.3mln is being invested into IMM from an issue of unsecured convertible securities and associated options to L1 Capital Global Opportunities Master Fund and Lind Global Macro Fund.

Quick facts: ImmuPharma PLC

Price: 14 GBX

AIM:IMM
Market: AIM
Market Cap: £25.62 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 down as Lloyd's of London expects claims to be...

Headlines from the Proactive UK newsroom. The FTSE 100 opened lower on fears that a second wave of coronavirus infections is coming after upticks in Germany, China and South Korea. The blue chip index shed 76 points at 5,827 in morning trading. Hargreaves Lansdown PLC (LON:HL.) has vowed...

on 14/5/20

2 min read